A
129.90
3.24 (2.56%)
| Previous Close | 126.66 |
| Open | 127.70 |
| Volume | 381,556 |
| Avg. Volume (3M) | 623,962 |
| Market Cap | 7,762,875,392 |
| Price / Sales | 21.22 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -154.12% |
| Operating Margin (TTM) | -370.18% |
| Diluted EPS (TTM) | -9.15 |
| Quarterly Revenue Growth (YOY) | -24.00% |
| Current Ratio (MRQ) | 0.740 |
| Operating Cash Flow (TTM) | -330.08 M |
| Levered Free Cash Flow (TTM) | -104.13 M |
| Return on Assets (TTM) | -27.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ascendis Pharma A/S | Bearish | Bullish |
AIStockmoo Score
1.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 104.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 207.00 (Stifel, 59.35%) | Buy |
| Median | 180.00 (38.57%) | |
| Low | 153.00 (TD Cowen, 17.78%) | Buy |
| Average | 179.43 (38.13%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 129.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 15 Nov 2024 | 170.00 (30.87%) | Buy | 126.51 |
| 04 Nov 2024 | 170.00 (30.87%) | Buy | 125.77 | |
| Oppenheimer | 15 Nov 2024 | 180.00 (38.57%) | Buy | 126.51 |
| Stifel | 15 Nov 2024 | 207.00 (59.35%) | Buy | 126.51 |
| TD Cowen | 15 Nov 2024 | 153.00 (17.78%) | Buy | 126.51 |
| 21 Oct 2024 | 160.00 (23.17%) | Buy | 128.66 | |
| Wedbush | 15 Nov 2024 | 181.00 (39.34%) | Buy | 126.51 |
| JP Morgan | 23 Oct 2024 | 174.00 (33.95%) | Buy | 127.69 |
| B of A Securities | 23 Sep 2024 | 191.00 (47.04%) | Buy | 146.60 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |